• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溴隐亭对急性刺激引起的血浆醛固酮反应的调节作用。

Bromocriptine-induced modulation of plasma aldosterone response to acute stimulations.

作者信息

Birkhäuser M, Riondel A, Vallotton M B

出版信息

Acta Endocrinol (Copenh). 1979 Jun;91(2):294-302. doi: 10.1530/acta.0.0910294.

DOI:10.1530/acta.0.0910294
PMID:223355
Abstract

The influence of the dopaminergic agent 2-bromoergocryptine on plasma aldosterone response to acute stimulations was assessed in 14 normal male volunteers. Without modifying basal plasma aldosterone levels or urinary aldosterone excretion, bromocriptine retarded and diminished significantly the plasma aldosterone response to angiotensin II or ACTH, but did not alter the response to upright posture. These results point to a bromocriptine-induced modulation of the plasma aldosterone response to direct stimulations at the adrenal level. The present work brings further evidence for an effect of the dopaminergic system on the physiological control of aldosterone.

摘要

在14名正常男性志愿者中评估了多巴胺能药物2-溴麦角隐亭对血浆醛固酮急性刺激反应的影响。溴隐亭在不改变基础血浆醛固酮水平或尿醛固酮排泄的情况下,显著延迟并减弱了血浆醛固酮对血管紧张素II或促肾上腺皮质激素的反应,但未改变对直立姿势的反应。这些结果表明,溴隐亭可诱导血浆醛固酮对肾上腺水平直接刺激的反应发生调节。本研究为多巴胺能系统对醛固酮生理控制的作用提供了进一步的证据。

相似文献

1
Bromocriptine-induced modulation of plasma aldosterone response to acute stimulations.溴隐亭对急性刺激引起的血浆醛固酮反应的调节作用。
Acta Endocrinol (Copenh). 1979 Jun;91(2):294-302. doi: 10.1530/acta.0.0910294.
2
Dopaminergic control of plasma catecholamine and aldosterone responses to acute stimuli in normal man.多巴胺能对正常男性血浆儿茶酚胺和醛固酮对急性刺激反应的调控
J Clin Endocrinol Metab. 1980 Oct;51(4):724-9. doi: 10.1210/jcem-51-4-724.
3
Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone.甲氧氯普胺和溴隐亭对人体肾素-血管紧张素-醛固酮系统的作用。醛固酮的多巴胺能调控。
J Clin Invest. 1979 Apr;63(4):727-35. doi: 10.1172/JCI109356.
4
Effect of bromocriptine on the control of plasma aldosterone diurnal variation in normal supine man.
Horm Res. 1979;10(2-3):64-78. doi: 10.1159/000178990.
5
Effect of bromocriptine treatment on the aldosterone response to angiotensin II and adrenocorticotropin in idiopathic hyperaldosteronism.
J Clin Endocrinol Metab. 1985 Jul;61(1):192-5. doi: 10.1210/jcem-61-1-192.
6
Aldosterone and renin-angiotensin responses to stimuli in patients with treated congestive heart failure.醛固酮和肾素 - 血管紧张素对已接受治疗的充血性心力衰竭患者刺激的反应。
J Lab Clin Med. 1976 Jun;87(6):1005-15.
7
Circadian rhythm of plasma aldosterone and time dependent alterations of aldosterone regulators.
J Steroid Biochem. 1984 Jan;20(1):321-3. doi: 10.1016/0022-4731(84)90225-5.
8
[Effects of low salt plus upright posture, angiotensin II, ACTH, and potassium upon plasma renin activity, aldosterone, and cortisol (author's transl)].
Nihon Naibunpi Gakkai Zasshi. 1975 Sep 20;51(9):740-4. doi: 10.1507/endocrine1927.51.9_740.
9
Effects of bromocriptine on renin, aldosterone, and prolactin responses to posture and metoclopramide in idiopathic edema: possible therapeutic approach.溴隐亭对特发性水肿患者肾素、醛固酮及催乳素对体位和甲氧氯普胺反应的影响:可能的治疗方法
J Clin Endocrinol Metab. 1982 Mar;54(3):510-6. doi: 10.1210/jcem-54-3-510.
10
Role of dopamine in the regulation of aldosterone and 18-hydroxycorticosterone secretion in man.多巴胺在人体醛固酮和18-羟皮质酮分泌调节中的作用。
J Endocrinol Invest. 1984 Oct;7(5):473-9. doi: 10.1007/BF03348453.

引用本文的文献

1
Effects of the dopaminergic agonist cianergoline on blood pressure, the renin-angiotensin-aldosterone axis and the sympathetic nervous system in patients with essential hypertension.多巴胺能激动剂西阿尼戈林对原发性高血压患者血压、肾素-血管紧张素-醛固酮轴及交感神经系统的影响
Eur J Clin Pharmacol. 1985;29(1):25-31. doi: 10.1007/BF00547364.
2
Stimulation of aldosterone secretion by metoclopramide is not affected by chronic converting enzyme inhibition.
Eur J Clin Pharmacol. 1985;29(2):207-10. doi: 10.1007/BF00547423.